Condition: Thrombocytopenia, Neonatal Alloimmune · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| UC Davis School of Medicine | Sacramento, California, United States | Recruiting |
| Childrens Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Advocate Children's Hospital | Park Ridge, Illinois, United States | Recruiting |
| University of Iowa Hospital and Clinics | Iowa City, Iowa, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| Oregon Health And Science University | Portland, Oregon, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Texas Medical Branch | Galveston, Texas, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06533098